Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immune checkpoint inhibitor-related hepatotoxicity: A review
Devika Remash, David Prince, Catriona McKenzie, et al.
World Journal of Gastroenterology (2021) Vol. 27, Iss. 32, pp. 5376-5391
Open Access | Times Cited: 82

Showing 1-25 of 82 citing articles:

Radiotherapy combined with immunotherapy: the dawn of cancer treatment
Zengfu Zhang, Xu Liu, Dawei Chen, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 359
Immune-related adverse events of immune checkpoint inhibitors: a review
Qinan Yin, Liuyun Wu, Lizhu Han, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 139
Acute Liver Failure Guidelines
Alexandra Shingina, Nizar A. Mukhtar, Jamilé Wakim-Fleming, et al.
The American Journal of Gastroenterology (2023) Vol. 118, Iss. 7, pp. 1128-1153
Open Access | Times Cited: 84
Emerging Role of Circular RNAs in Hepatocellular Carcinoma Immunotherapy
Tasneem Abaza, Mostafa K. Abd El‐Aziz, Kerolos Ashraf Daniel, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 22, pp. 16484-16484
Open Access | Times Cited: 49
Analysis of risk factors for immune checkpoint inhibitor-associated liver injury: a retrospective analysis based on clinical study and real-world data
Bitao Wang, Shaowei Zhuang, Shengnan Lin, et al.
Hepatology International (2025)
Closed Access | Times Cited: 1
Drug‐Induced Liver Injury: Clinical Evidence of N‐Acetyl Cysteine Protective Effects
Yonela Ntamo, Khanyisani Ziqubu, Nireshni Chellan, et al.
Oxidative Medicine and Cellular Longevity (2021) Vol. 2021, Iss. 1
Open Access | Times Cited: 53
Treatment of Drug-Induced Liver Injury
Rolf Teschke
Biomedicines (2022) Vol. 11, Iss. 1, pp. 15-15
Open Access | Times Cited: 27
Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events
Alexander Coukos, Julien Vionnet, Michel Obéid, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 10, pp. e005635-e005635
Open Access | Times Cited: 23
An Immunological Perspective on the Mechanism of Drug Induced Liver Injury: Focused on Drugs for Treatment of Hepatocellular Carcinoma and Liver Transplantation
Soon Kyu Lee, Jong Young Choi, Eun Sun Jung, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 5002-5002
Open Access | Times Cited: 14
MCL1 inhibition targets Myeloid Derived Suppressors Cells, promotes antitumor immunity and enhances the efficacy of immune checkpoint blockade
Nabanita Mukherjee, Elizabeth Katsnelson, Tonya M. Brunetti, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 3
Open Access | Times Cited: 5
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma and Their Hepatic-Related Side Effects: A Review
Thomas Ruli, Ethan D. Pollack, Atul Lodh, et al.
Cancers (2024) Vol. 16, Iss. 11, pp. 2042-2042
Open Access | Times Cited: 5
Liver Transplantation for Hepatocellular Carcinoma after Downstaging or Bridging Therapy with Immune Checkpoint Inhibitors
Qimeng Gao, Imran J. Anwar, Nader Abraham, et al.
Cancers (2021) Vol. 13, Iss. 24, pp. 6307-6307
Open Access | Times Cited: 32
Immunotherapy-induced Hepatotoxicity: A Review
Teresa Da Cunha, George Y. Wu, Haleh Vaziri
Journal of Clinical and Translational Hepatology (2022) Vol. 000, Iss. 000, pp. 000-000
Open Access | Times Cited: 21
Multiorgan Toxicity from Dual Checkpoint Inhibitor Therapy, Resulting in a Complete Response—A Case Report
Skaistė Astašauskaitė, Rita Kupčinskaitė-Noreikienė, Inga Zaborienė, et al.
Medicina (2024) Vol. 60, Iss. 7, pp. 1129-1129
Open Access | Times Cited: 4
Immune-checkpoint Inhibitors in Anti-cancer Armamentarium: a Double-edged Sword in Risk of Developing Autoimmunity and Immune-related Adverse Effects

Frontiers research topics (2025)
Closed Access
Treatment Experience in Managing Severe Immune-Mediated Hepatotoxicity Induced by Immune Checkpoint Inhibitors
Ruijie Cao, Shasha Zhang, Jingjing Zhang, et al.
(2025)
Closed Access
Clinical Manifestations and Risk Factors of Liver Injury Induced by PD-1 Inhibitors in Patients with Malignancies: A Case-Control Study
Pengfei Zhao, Lihong Yu, Wenming Ma, et al.
Therapeutics and Clinical Risk Management (2025) Vol. Volume 21, pp. 309-320
Open Access
Epigenetic regulators combined with tumour immunotherapy: current status and perspectives
Huan Zhang, Yuepeng Pang, Ling Yi, et al.
Clinical Epigenetics (2025) Vol. 17, Iss. 1
Open Access
Cemiplimab and diabetic ketoacidosis: a case report of a rare endocrinopathy associated with immune checkpoint inhibitors
Anna Arecco, Cristian Petolicchio, Alessandro Pastorino, et al.
Frontiers in Endocrinology (2025) Vol. 16
Open Access
Erkennen und Behandeln von Nebenwirkungen der Immuntherapie
Catherine Leyh, Christoph Roderburg, Tom Lüdde
Deleted Journal (2025)
Closed Access
Immunotherapy in liver transplantation for hepatocellular carcinoma: Pros and cons
Yi Luo, Fei Teng, Hong Fu, et al.
World Journal of Gastrointestinal Oncology (2022) Vol. 14, Iss. 1, pp. 163-180
Open Access | Times Cited: 18
Immunosuppression management for refractory checkpoint inhibitor-related hepatotoxicity
Gres Karim, Megha Reddy, Navim Mobin, et al.
Clinical Liver Disease (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 3
HBV reactivation and clinical resolution in an isolated anti-HBc-positive patient during immune checkpoint inhibition
Lukas S. Baumert, Angela Shih, Raymond Chung
Med (2024) Vol. 5, Iss. 2, pp. 126-131.e1
Open Access | Times Cited: 3
Clinical Outcomes of Immune Checkpoint Inhibitor Diabetes Mellitus at a Comprehensive Cancer Center
Rebecca Jeun, Priyanka Iyer, Conor Best, et al.
Immunotherapy (2023) Vol. 15, Iss. 6, pp. 417-428
Closed Access | Times Cited: 9
Hepatotoxicity Associated with Immune Checkpoint Inhibitors in Clinical Practice: A Study Leveraging Data from the US Food and Drug Administration's Adverse Event Reporting System
Haozhou Wang, Hui Yang, Xiaoguang Zhou, et al.
Clinical Therapeutics (2023) Vol. 45, Iss. 2, pp. 151-159
Closed Access | Times Cited: 8
Page 1 - Next Page

Scroll to top